Bardoxolone methyl is a potential therapy for PAH that reduces oxidative stress and NF‐κB activation by activating Nrf2, promoting antioxidant gene transcription, and enhancing oxidative phosphorylation [554]. This evidence concerns the gene NFKB1 and pulmonary arterial hypertension.